Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Omacetaxine Mepesuccinate in FLT3-ITD AML
NCT03170895Phase 2Completed
- Sponsor
- The University of Hong Kong
- Start
- Jul 2017
- Primary completion
- Feb 2020
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of homoharringtonine in acute myeloid leukemia (AML), sponsored by The University of Hong Kong. Started Jul 2017; status: completed.
02
Drugs
homoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03170895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03170895.